pyrazinamide has been researched along with Leishmaniasis, Mucocutaneous in 1 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
Leishmaniasis, Mucocutaneous: A disease characterized by the chronic, progressive spread of lesions from New World cutaneous leishmaniasis caused by species of the L. braziliensis complex to the nasal, pharyngeal, and buccal mucosa some time after the appearance of the initial cutaneous lesion. Nasal obstruction and epistaxis are frequent presenting symptoms.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Escobar, MA | 1 |
| Saravia, NG | 1 |
| Weigle, KA | 1 |
1 other study available for pyrazinamide and Leishmaniasis, Mucocutaneous
| Article | Year |
|---|---|
Concurrent mucosal leishmaniasis and pulmonary tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Contraindications; Drug Therapy, Combin | 1996 |